We provide a variety of sequencing services. These includes not only the preparation of the samples using various automated platforms, but also Next-Generation Sequencing (NGS) on different platforms (HiSeq, MiSeq, and IonTorrent PGM). We can provide additional data analysis options, with the choice to receive raw sequencing data through to processed and filtered variant call files.
Using next-generation sequencing, it is possible to analyze about 2 billion sequences in parallel equating to more than 180 billion bases per day. In comparison to traditional Sanger sequencing, where only single sequences can be analyzed, NGS offers significant advantages including cost and time savings.
Whole exome sequencing enables the analysis of the entire protein coding region of a sample, which can then be compared across multiple exomes. Our experience extends from population genetics to tumor diagnostics.
Using transcriptome sequencing, analysis of all RNA molecules of a biological sample at a specific time-point, are detected and quantified. This analysis has wide-ranging capabilities and applications.
As a next-generation sequencing service provider CeGaT makes its expertise also available to publicly funded projects. We are currently a partner of the following projects and programs:
The CAM-PaC project deals with the integrative analysis of gene functions in different cellular and animal models of pancreatic cancer. Initially, novel cellular and animal models, as well as novel strategies, will be developed to generate large scale metabolic, transcriptomic and genetic data. On this basis, novel therapeutic options and bioinformatic models for predictive diagnostics can be developed. CeGaT is contributing to the consortium by providing its expertise in transcriptomic profiling and interpretation. The first step is the establishment of routine protocols for quantitative interpretation of transcriptomes of clonal-sphere-cultures (CSC) consisting of approximately 40 – 100 individual cells.
In the DESIRE project, novel strategies will be developed to advance the diagnosis, prevention and treatment of children with difficult-to-treat epilepsy. An important milestone includes the development and identification of different diagnostic tools and biomarkers in order to enable a standardized diagnosis and patient stratification. In this context, CeGaT will identify miRNA biomarkers from thrombocytes and will validate how these biomarkers can be used for the diagnosis and the prediction of progression of disease.
IonNeurONet is a research network that is supported by the Rare Disease Program of the Federal Ministry of Education and Research. The goal of IonNeurONet is the identification of novel genetic defects causing ion channel diseases. In addition, the network addresses the elucidation of pathophysiological mechanisms leading to these diseases. CeGaT carries out exome sequencing in affected families and has developed a special diagnostic panel for the diagnosis of ion channel diseases.
The PONS project aims at the development of a better predictive test system for a drug compound profiling based on neuronals cells derived from schizophrenic patients. In this context, CeGaT will use neuronal samples from animal or cellular models that have been derived from induced pluripotent stem cells. Expression levels of mRNA and miRNA levels will be determined quantitatively, making it possible to create a molecular “fingerprint” of the disease phenotype and to estimate the success of novel drug therapies by analyzing transcriptomic patterns.